Memory Pharmaceuticals Corp. Profile

Memory Pharmaceuticals Corp.

operates as a biopharmaceutical company in the United States.

It develops drugs for the treatment of central nervous system disorders, such as Alzheimer''s disease, schizophrenia, depression, vascular dementia, mild cognitive impairment, and memory impairments associated with aging.

The company has five clinical and preclinical stages drugs.

Its products include MEM 1003, MEM 1414, MEM 1917, and MEM 63908 for the treatment of Alzheimer’s disease, vascular dementia, and mild cognitive impairment; and MEM 3454 for the treatment of schizophrenia.

The company has collaborations with F.

Hoffmann-La Roche, Ltd.

and Hoffmann-La Roche, Inc.

for the development of its PDE4 inhibitors, including MEM 1414 and MEM 1917; and nicotinic alpha-7 partial agonists, including MEM 3454 and MEM 63908.

Memory Pharmaceuticals was organized in 1997 and is based in Montvale, New Jersey.

 

 

 


© 2001 - 2008 Lexdon Business Library
IC9700 Certified
Privacy Policy
eTrust Privacy Certified